Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context
Summary: Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in patients with T2D. Methods: We included patients wit...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776224000139 |
| _version_ | 1827365261473218560 |
|---|---|
| author | Gian Paolo Fadini Enrico Longato Mario Luca Morieri Stefano Del Prato Angelo Avogaro Anna Solini Mariella Baldassarre Agostino Consoli Sara Morganet Antonella Zugaro Marco Giorgio Baroni Francesco Andreozzi Adriano Gatti Adriano Gatti Stefano De Riu Andrea Del Buono Raffaella Aldigeri Riccardo Bonadonna Alessandra Dei Cas Angela Vazzana Monica Antonini Valentina Moretti Patrizia Li Volsi Miranda Cesare Giorgio Zanette Silvia Carletti Paola D'Angelo Gaetano Leto Frida Leonetti Luca D'Onofrio Ernesto Maddaloni Raffaella Buzzetti Simona Frontoni Giselle Cavallo Susanna Morano Tiziana Filardi Umberto Capece Andrea Giaccari Antonio C. Bossi Giancarla Meregalli Fabrizio Querci Alessia Gaglio Veronica Resi Emanuela Orsi Stefano Fazion Ivano G. Franzetti Cesare Berra Silvia Manfrini Gabriella Garrapa Giulio Lucarelli Lara Riccialdelli Elena Tortato Marco Zavattaro Gianluca Aimaretti Franco Cavalot Guglielmo Beccuti Fabio Broglio Bruno Fattor Giuliana Cazzetta Olga Lamacchia Anna Rauseo Salvatore De Cosmo Rosella Cau Mariangela Ghiani Antonino Di Benedetto Antonino Di Pino Salvatore Piro Francesco Purrello Lucia Frittitta Agostino Milluzzo Giuseppina Russo |
| author_facet | Gian Paolo Fadini Enrico Longato Mario Luca Morieri Stefano Del Prato Angelo Avogaro Anna Solini Mariella Baldassarre Agostino Consoli Sara Morganet Antonella Zugaro Marco Giorgio Baroni Francesco Andreozzi Adriano Gatti Adriano Gatti Stefano De Riu Andrea Del Buono Raffaella Aldigeri Riccardo Bonadonna Alessandra Dei Cas Angela Vazzana Monica Antonini Valentina Moretti Patrizia Li Volsi Miranda Cesare Giorgio Zanette Silvia Carletti Paola D'Angelo Gaetano Leto Frida Leonetti Luca D'Onofrio Ernesto Maddaloni Raffaella Buzzetti Simona Frontoni Giselle Cavallo Susanna Morano Tiziana Filardi Umberto Capece Andrea Giaccari Antonio C. Bossi Giancarla Meregalli Fabrizio Querci Alessia Gaglio Veronica Resi Emanuela Orsi Stefano Fazion Ivano G. Franzetti Cesare Berra Silvia Manfrini Gabriella Garrapa Giulio Lucarelli Lara Riccialdelli Elena Tortato Marco Zavattaro Gianluca Aimaretti Franco Cavalot Guglielmo Beccuti Fabio Broglio Bruno Fattor Giuliana Cazzetta Olga Lamacchia Anna Rauseo Salvatore De Cosmo Rosella Cau Mariangela Ghiani Antonino Di Benedetto Antonino Di Pino Salvatore Piro Francesco Purrello Lucia Frittitta Agostino Milluzzo Giuseppina Russo |
| author_sort | Gian Paolo Fadini |
| collection | DOAJ |
| description | Summary: Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in patients with T2D. Methods: We included patients with T2D who initiated dapagliflozin or comparators from 2015 to 2020. Propensity score matching (PSM) was performed to balance the two groups. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) from baseline to the end of observation. Secondary endpoints included changes in albuminuria and loss of kidney function. Findings: We analysed two matched groups of 6197 patients each. The comparator group included DPP-4 inhibitors (40%), GLP-1RA (22.3%), sulphonylureas (16.1%), pioglitazone (8%), metformin (5.8%), or acarbose (4%). Only 6.4% had baseline eGFR <60 ml/min/1.73 m2 and 15% had UACR >30 mg/g. During a mean follow-up of 2.5 year, eGFR declined significantly less in the dapagliflozin vs comparator group by 1.81 ml/min/1.73 m2 (95% C.I. from 1.13 to 2.48; p < 0.0001). The mean eGFR slope was significantly less negative in the dapagliflozin group by 0.67 ml/min/1.73 m2/year (95% C.I. from 0.47 to 0.88; p < 0.0001). Albuminuria declined significantly in new-users of dapagliflozin within 6 months and remained on average 44.3 mg/g lower (95% C.I. from −66.9 to −21.7; p < 0.0001) than in new-users of comparators. New-users of dapagliflozin had significantly lower rates of new-onset CKD, loss of kidney function, and a composite renal outcome. Results were confirmed for all SGLT2 inhibitors, in patients without baseline CKD, and when GLP-1RA were excluded from comparators. Interpretation: Initiating dapagliflozin improved kidney function outcomes and albuminuria in patients with T2D and a low renal risk. Funding: Funded by the Italian Diabetes Society and partly supported by a grant from AstraZeneca. |
| first_indexed | 2024-03-08T08:25:44Z |
| format | Article |
| id | doaj.art-af262c8fdded4a0983a289dedffa98cc |
| institution | Directory Open Access Journal |
| issn | 2666-7762 |
| language | English |
| last_indexed | 2024-03-08T08:25:44Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj.art-af262c8fdded4a0983a289dedffa98cc2024-02-02T04:40:33ZengElsevierThe Lancet Regional Health. Europe2666-77622024-03-0138100847Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in contextGian Paolo Fadini0Enrico Longato1Mario Luca Morieri2Stefano Del Prato3Angelo Avogaro4Anna Solini5Mariella BaldassarreAgostino ConsoliSara MorganetAntonella ZugaroMarco Giorgio BaroniFrancesco AndreozziAdriano GattiAdriano GattiStefano De RiuAndrea Del BuonoRaffaella AldigeriRiccardo BonadonnaAlessandra Dei CasAngela VazzanaMonica AntoniniValentina MorettiPatrizia Li VolsiMiranda CesareGiorgio ZanetteSilvia CarlettiPaola D'AngeloGaetano LetoFrida LeonettiLuca D'OnofrioErnesto MaddaloniRaffaella BuzzettiSimona FrontoniGiselle CavalloSusanna MoranoTiziana FilardiUmberto CapeceAndrea GiaccariAntonio C. BossiGiancarla MeregalliFabrizio QuerciAlessia GaglioVeronica ResiEmanuela OrsiStefano FazionIvano G. FranzettiCesare BerraSilvia ManfriniGabriella GarrapaGiulio LucarelliLara RiccialdelliElena TortatoMarco ZavattaroGianluca AimarettiFranco CavalotGuglielmo BeccutiFabio BroglioBruno FattorGiuliana CazzettaOlga LamacchiaAnna RauseoSalvatore De CosmoRosella CauMariangela GhianiAntonino Di BenedettoAntonino Di PinoSalvatore PiroFrancesco PurrelloLucia FrittittaAgostino MilluzzoGiuseppina RussoDivision of Metabolic Diseases, Department of Medicine, University of Padova, 35128 Padova, Italy; Laboratory of Experimental Diabetology, Veneto Institute of Molecular Medicine, 35128 Padova, Italy; Corresponding author. Department of Medicine, University of Padova, Italy.Department of Information Engineering, University of Padova, 35100 Padua, ItalyDivision of Metabolic Diseases, Department of Medicine, University of Padova, 35128 Padova, ItalyDepartment of Clinical & Experimental Medicine, University of Pisa and Sant’Anna School of Advanced Studies, 56126 Pisa, ItalyDivision of Metabolic Diseases, Department of Medicine, University of Padova, 35128 Padova, ItalyDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, ItalySummary: Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in patients with T2D. Methods: We included patients with T2D who initiated dapagliflozin or comparators from 2015 to 2020. Propensity score matching (PSM) was performed to balance the two groups. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) from baseline to the end of observation. Secondary endpoints included changes in albuminuria and loss of kidney function. Findings: We analysed two matched groups of 6197 patients each. The comparator group included DPP-4 inhibitors (40%), GLP-1RA (22.3%), sulphonylureas (16.1%), pioglitazone (8%), metformin (5.8%), or acarbose (4%). Only 6.4% had baseline eGFR <60 ml/min/1.73 m2 and 15% had UACR >30 mg/g. During a mean follow-up of 2.5 year, eGFR declined significantly less in the dapagliflozin vs comparator group by 1.81 ml/min/1.73 m2 (95% C.I. from 1.13 to 2.48; p < 0.0001). The mean eGFR slope was significantly less negative in the dapagliflozin group by 0.67 ml/min/1.73 m2/year (95% C.I. from 0.47 to 0.88; p < 0.0001). Albuminuria declined significantly in new-users of dapagliflozin within 6 months and remained on average 44.3 mg/g lower (95% C.I. from −66.9 to −21.7; p < 0.0001) than in new-users of comparators. New-users of dapagliflozin had significantly lower rates of new-onset CKD, loss of kidney function, and a composite renal outcome. Results were confirmed for all SGLT2 inhibitors, in patients without baseline CKD, and when GLP-1RA were excluded from comparators. Interpretation: Initiating dapagliflozin improved kidney function outcomes and albuminuria in patients with T2D and a low renal risk. Funding: Funded by the Italian Diabetes Society and partly supported by a grant from AstraZeneca.http://www.sciencedirect.com/science/article/pii/S2666776224000139Type 2 diabetesChronic kidney diseaseSGLT2 inhibitorsPreventionObservational |
| spellingShingle | Gian Paolo Fadini Enrico Longato Mario Luca Morieri Stefano Del Prato Angelo Avogaro Anna Solini Mariella Baldassarre Agostino Consoli Sara Morganet Antonella Zugaro Marco Giorgio Baroni Francesco Andreozzi Adriano Gatti Adriano Gatti Stefano De Riu Andrea Del Buono Raffaella Aldigeri Riccardo Bonadonna Alessandra Dei Cas Angela Vazzana Monica Antonini Valentina Moretti Patrizia Li Volsi Miranda Cesare Giorgio Zanette Silvia Carletti Paola D'Angelo Gaetano Leto Frida Leonetti Luca D'Onofrio Ernesto Maddaloni Raffaella Buzzetti Simona Frontoni Giselle Cavallo Susanna Morano Tiziana Filardi Umberto Capece Andrea Giaccari Antonio C. Bossi Giancarla Meregalli Fabrizio Querci Alessia Gaglio Veronica Resi Emanuela Orsi Stefano Fazion Ivano G. Franzetti Cesare Berra Silvia Manfrini Gabriella Garrapa Giulio Lucarelli Lara Riccialdelli Elena Tortato Marco Zavattaro Gianluca Aimaretti Franco Cavalot Guglielmo Beccuti Fabio Broglio Bruno Fattor Giuliana Cazzetta Olga Lamacchia Anna Rauseo Salvatore De Cosmo Rosella Cau Mariangela Ghiani Antonino Di Benedetto Antonino Di Pino Salvatore Piro Francesco Purrello Lucia Frittitta Agostino Milluzzo Giuseppina Russo Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context The Lancet Regional Health. Europe Type 2 diabetes Chronic kidney disease SGLT2 inhibitors Prevention Observational |
| title | Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context |
| title_full | Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context |
| title_fullStr | Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context |
| title_full_unstemmed | Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context |
| title_short | Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal riskResearch in context |
| title_sort | long term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care a comparative effectiveness study on propensity score matched cohorts at low renal riskresearch in context |
| topic | Type 2 diabetes Chronic kidney disease SGLT2 inhibitors Prevention Observational |
| url | http://www.sciencedirect.com/science/article/pii/S2666776224000139 |
| work_keys_str_mv | AT gianpaolofadini longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT enricolongato longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT mariolucamorieri longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT stefanodelprato longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT angeloavogaro longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT annasolini longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT mariellabaldassarre longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT agostinoconsoli longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT saramorganet longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT antonellazugaro longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT marcogiorgiobaroni longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT francescoandreozzi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT adrianogatti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT adrianogatti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT stefanoderiu longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT andreadelbuono longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT raffaellaaldigeri longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT riccardobonadonna longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT alessandradeicas longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT angelavazzana longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT monicaantonini longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT valentinamoretti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT patrizialivolsi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT mirandacesare longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT giorgiozanette longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT silviacarletti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT paoladangelo longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT gaetanoleto longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT fridaleonetti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT lucadonofrio longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT ernestomaddaloni longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT raffaellabuzzetti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT simonafrontoni longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT gisellecavallo longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT susannamorano longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT tizianafilardi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT umbertocapece longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT andreagiaccari longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT antoniocbossi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT giancarlameregalli longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT fabrizioquerci longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT alessiagaglio longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT veronicaresi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT emanuelaorsi longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT stefanofazion longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT ivanogfranzetti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT cesareberra longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT silviamanfrini longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT gabriellagarrapa longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT giuliolucarelli longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT larariccialdelli longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT elenatortato longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT marcozavattaro longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT gianlucaaimaretti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT francocavalot longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT guglielmobeccuti longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT fabiobroglio longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT brunofattor longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT giulianacazzetta longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT olgalamacchia longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT annarauseo longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT salvatoredecosmo longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT rosellacau longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT mariangelaghiani longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT antoninodibenedetto longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT antoninodipino longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT salvatorepiro longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT francescopurrello longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT luciafrittitta longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT agostinomilluzzo longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext AT giuseppinarusso longtermbenefitsofdapagliflozinonrenaloutcomesoftype2diabetesunderroutinecareacomparativeeffectivenessstudyonpropensityscorematchedcohortsatlowrenalriskresearchincontext |